Intravenous Zotatifin in Adults With Mild or Moderate COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 1, 2021

Primary Completion Date

January 12, 2023

Study Completion Date

September 22, 2023

Conditions
Corona Virus Infection
Interventions
DRUG

Zotatifin

Zotatifin is a potent and sequence-selective inhibitor of eukaryotic translation initiation factor (eIF) 4A1-mediated translation that imparts its regulation through a reversible enhancement of eIF4A1 binding to RNAs (ribonucleic acids) with specific polypurine motifs within the 5'-untranslated region (UTR).

DRUG

Placebo

5% dextrose injection, USP

Trial Locations (4)

20814

National Institute of Allergy and Infectious Diseases, Bethesda

33606

Tampa General Hospital, Tampa

35055

Cullman Clinical Trials, Cullman

36207

Pinnacle Research Group, Anniston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

Effector Therapeutics

INDUSTRY